Jove
Visualize
Contact Us

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy01:27

Tumor Immunotherapy

659
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
659
Cytotoxic T Cells-mediated Immune Response01:27

Cytotoxic T Cells-mediated Immune Response

1.9K
Cytotoxic T cells are a vital component of the immune system. They have the remarkable ability to identify and target antigens on infected or abnormal cells. These antigens often originate from intracellular pathogens such as viruses or abnormal proteins cancer cells produce.
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...
1.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A tumor suppressor role of the miR-15b/16-2 cluster in T-cell acute lymphoblastic leukemia.

Blood·2026
Same author

Impact of TP53 alterations on outcomes in pediatric and young adult patients with relapsed / refractory B-cell acute lymphoblastic leukemia after CD19-CAR T-Cell therapy.

Bone marrow transplantation·2026
Same author

miRNA profiling in pediatric and young adult Burkitt leukemia and lymphoma.

Virchows Archiv : an international journal of pathology·2026
Same author

PD-1 Expression Promotes Immune Evasion in B-ALL.

Hematology reports·2025
Same author

surviBALL: exploring lncRNA expression at diagnosis for 5-year EFS risk stratification in pediatric B-ALL-a proof of concept.

Molecular and cellular pediatrics·2025
Same author

Optimized protocol for intracellular labeling of red blood cells with anti-hemoglobin F for confocal microscopy analysis.

Micron (Oxford, England : 1993)·2025
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Sep 9, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K

Pre-TCR-targeted immunotherapy for T cell acute lymphoblastic leukemia.

Patricia Fuentes1, Marina García-Peydró1, Juan Alcain1

  • 1Immune System Development and Function Unit. Centro de Biología Molecular Severo Ochoa, Consejo Superior de Investigaciones Científicas (CSIC) and Universidad Autónoma de Madrid (UAM), Madrid, Spain.

Nature Immunology
|September 1, 2025
PubMed
Summary

Targeting the pre-T cell receptor (pre-TCR) offers a new immunotherapy for T cell acute lymphoblastic leukemia (T-ALL). This approach effectively inhibits leukemia-initiating cells and tumor growth in preclinical models.

More Related Videos

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.4K

Related Experiment Videos

Last Updated: Sep 9, 2025

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

15.3K
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

18.2K
Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model
06:08

Assessment of Chimeric Antigen Receptor T Cell-Associated Toxicities Using an Acute Lymphoblastic Leukemia Patient-Derived Xenograft Mouse Model

Published on: February 10, 2023

1.4K

Area of Science:

  • Immunology
  • Oncology
  • Molecular Biology

Background:

  • T cell acute lymphoblastic leukemia (T-ALL) is an aggressive cancer with limited treatment options for relapsed/refractory cases.
  • Targeting T-ALL is difficult due to shared antigens between leukemic and normal T cells.
  • Leukemia-initiating cells (LICs) drive T-ALL progression and are key therapeutic targets.

Purpose of the Study:

  • To identify novel biomarkers for T-ALL LICs.
  • To evaluate the pre-T cell receptor (pre-TCR) as a therapeutic target for T-ALL.
  • To develop and validate targeted immunotherapies against pre-TCR in T-ALL.

Main Methods:

  • Identification of pre-TCR as a T-ALL LIC biomarker in human samples.
  • Loss-of-function genetic studies in mouse xenografts to assess pre-TCR signaling necessity.
  • Development and in vivo validation of anti-pTα monoclonal antibody and antibody-drug conjugate therapies.

Main Results:

  • Pre-TCR is a specific biomarker for T-ALL LICs.
  • Pre-TCR signaling is essential for T-ALL LIC activity and tumor progression.
  • Anti-pTα antibody-drug conjugate therapy effectively inhibits LICs and T-ALL progression in vivo.

Conclusions:

  • The pre-T cell receptor is a viable and specific therapeutic target for T-ALL.
  • Targeting pre-TCR with antibody-drug conjugates shows promise as a potent immunotherapy for T-ALL.
  • This strategy offers a potential new treatment for relapsed/refractory T-ALL patients expressing pre-TCR.